j

Merck appoints Jessie English to lead discovery team

pharmafile | January 22, 2016 | Appointment | Research and Development Jessie English, Merck 

Merck has appointed Jessie English as the new vice president of discovery, translational innovation platform immuno-oncology, effective February 16, 2016.

English has a career spanning nearly two decades in oncology and immuno-oncology research. Most recently Jessie served as head of research at Belfer Institute for applied cancer science, the Dana-Farber Cancer Institute, and Harvard medical school.

In a statement, the company says: As with the appointment in November of Dr Laszlo Radvanyi as senior vice president, head of research in immuno-oncology, Jessie’s addition to the team is a further reflection of Merck’s commitment to building a team committed to reimagining immuno-oncology – relentlessly curious in their exploration of disease targets, yet focused on the modalities with the best chance of really helping patients.”

Related Content

acute_leukemia-all

Merck to acquire Curon Biopharmaceutical’s B-Cell Depletion Therapy

Merck have announced that they have entered into an agreement with private biotechnology company Curon …

Lung xray image

Merck and Daiichi Sankyo expand development and commericalisation agreement to include MK-6070

Daiichi Sankyo and Merck (known as MSD outside of the US and Canada) have announced …

CHMP gives positive opinion for Merck’s KEYTRUDA for unresectable or metastatic urothelial carcinoma

Merck (known as MSD outside of the US and Canada) has announced that its anti-PD-1 …

The Gateway to Local Adoption Series

Latest content